Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies

Background and objectives: Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen deprivation therapy is indicated. The aim of this paper is to present the results of five Phase 2 studies that asse...

Descripción completa

Detalles Bibliográficos
Autores principales: MacLean, Carol M., Ulys, Albertas, Jankevičius, Feliksas, Saladžinskas, Žilvinas, van Os, Steve, Larsen, Finn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146264/
https://www.ncbi.nlm.nih.gov/pubmed/37109639
http://dx.doi.org/10.3390/medicina59040681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146264/
https://www.ncbi.nlm.nih.gov/pubmed/37109639
http://dx.doi.org/10.3390/medicina59040681

Ejemplares similares